Literature DB >> 16940225

Hypertension produced by reductions in uterine perfusion in the pregnant rat: role of interleukin 6.

Giovani Gadonski1, B Babbette D LaMarca, Elizabeth Sullivan, William Bennett, Derrick Chandler, Joey P Granger.   

Abstract

The purpose of this study was to determine the role of interleukin (IL) 6 in mediating the increase in arterial pressure (AP) in response to chronic reductions in uterine perfusion pressure (RUPP) in pregnant rats. AP was higher in RUPP rats (138+/-1 mm Hg) than in normal pregnant (NP) rats (104+/-1 mm Hg). Serum IL-6 levels in the RUPP rats were 104.5+/-28.6 pg/mL as compared with 36.6+/-7.4 pg/mL in NP rats. To determine the long-term effects of a 2- to 3-fold elevation in plasma IL-6 on renal function and AP in pregnant rats, we infused IL-6 for 5 days (2.5 ng/day) in NP rats starting at day 14 of gestation. Five days later, serum IL-6 levels were 55.5+/-6.5 pg/mL in the control NP rats and 157.0+/-36.1 pg/mL in the IL-6-treated NP rats. AP was higher in the IL-6-treated NP rats (115+/-3 mm Hg) as compared with NP controls (101+/-1 mm Hg) at day 19 of gestation. Renal plasma flow and GFR were lower in the IL-6-treated NP rats than in the NP group. IL-6 increased plasma renin activity but did not affect endothelin in IL-6-treated NP rats. In contrast to the NP rats, IL-6 had no effect on AP or renal hemodynamics in virgin rats. In summary, these data indicate that plasma IL-6 is elevated in response to chronic reductions in uterine perfusion in pregnant rats and that a comparable elevation in plasma IL-6 increases AP and reduces renal function in pregnant rats.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16940225     DOI: 10.1161/01.HYP.0000238442.33463.94

Source DB:  PubMed          Journal:  Hypertension        ISSN: 0194-911X            Impact factor:   10.190


  75 in total

1.  Interleukin 6 knockout prevents angiotensin II hypertension: role of renal vasoconstriction and janus kinase 2/signal transducer and activator of transcription 3 activation.

Authors:  Michael W Brands; Amy K L Banes-Berceli; Edward W Inscho; Hind Al-Azawi; Ashlyn J Allen; Hicham Labazi
Journal:  Hypertension       Date:  2010-10-04       Impact factor: 10.190

2.  IL-6-induced pathophysiology during pre-eclampsia: potential therapeutic role for magnesium sulfate?

Authors:  Babbette Lamarca; Justin Brewer; Kedra Wallace
Journal:  Int J Interferon Cytokine Mediat Res       Date:  2011-07-01

3.  Recent insights into the pathophysiology of preeclampsia.

Authors:  Eric M George; Joey P Granger
Journal:  Expert Rev Obstet Gynecol       Date:  2010-09-01

4.  Endothelial dysfunction. An important mediator in the pathophysiology of hypertension during pre-eclampsia.

Authors:  B Lamarca
Journal:  Minerva Ginecol       Date:  2012-08

5.  The role of immune activation in contributing to vascular dysfunction and the pathophysiology of hypertension during preeclampsia.

Authors:  B Lamarca
Journal:  Minerva Ginecol       Date:  2010-04

6.  Interleukin-17 signaling mediates cytolytic natural killer cell activation in response to placental ischemia.

Authors:  Olivia K Travis; Dakota White; Cedar Baik; Chelsea Giachelli; Willie Thompson; Cassandra Stubbs; Mallory Greer; James P Lemon; Jan Michael Williams; Denise C Cornelius
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2020-04-22       Impact factor: 3.619

7.  Interleukin 6 underlies angiotensin II-induced hypertension and chronic renal damage.

Authors:  Weiru Zhang; Wei Wang; Hong Yu; Yujin Zhang; Yingbo Dai; Chen Ning; Lijian Tao; Hong Sun; Rodney E Kellems; Michael R Blackburn; Yang Xia
Journal:  Hypertension       Date:  2011-11-07       Impact factor: 10.190

Review 8.  Potential roles of angiotensin receptor-activating autoantibody in the pathophysiology of preeclampsia.

Authors:  Yang Xia; Susan M Ramin; Rodney E Kellems
Journal:  Hypertension       Date:  2007-06-18       Impact factor: 10.190

9.  Excess LIGHT contributes to placental impairment, increased secretion of vasoactive factors, hypertension, and proteinuria in preeclampsia.

Authors:  Wei Wang; Nicholas F Parchim; Takayuki Iriyama; Renna Luo; Cheng Zhao; Chen Liu; Roxanna A Irani; Weiru Zhang; Chen Ning; Yujin Zhang; Sean C Blackwell; Lieping Chen; Lijian Tao; M John Hicks; Rodney E Kellems; Yang Xia
Journal:  Hypertension       Date:  2013-12-09       Impact factor: 10.190

10.  Role of IL-6 -174(G/C) promoter polymorphism in the etiology of early-onset preeclampsia.

Authors:  Sabnavis Sowmya; Aruna Ramaiah; Pratibha Nallari; Akka Jyothy; Ananthapur Venkateshwari
Journal:  Inflamm Res       Date:  2015-04-28       Impact factor: 4.575

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.